1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline2. Hong, S, Won, YJ, Park, YR, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020; 52: 335–350.
Google Scholar | Crossref | Medline3. Gradishar, WJ, Anderson, BO, Abraham, J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020; 18: 452–478.
Google Scholar | Crossref | Medline4. Mauri, D, Kamposioras, K, Tsali, L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 2010; 36: 69–74.
Google Scholar | Crossref | Medline | ISI5. Gelderblom, H, Verweij, J, Nooter, K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590–1598.
Google Scholar | Crossref | Medline | ISI6. Scripture, CD, Figg, WD, Sparreboom, A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 2006; 4: 165–172.
Google Scholar | Crossref | Medline | ISI7. Singh, S, Dash, AK. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst 2009; 26: 333–372.
Google Scholar | Crossref | Medline8. Weiss, RB, Donehower, RC, Wiernik, PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263–1268.
Google Scholar | Crossref | Medline | ISI9. Gradishar, WJ, Tjulandin, S, Davidson, N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794–7803.
Google Scholar | Crossref | Medline | ISI10. Sparreboom, A, van Zuylen, L, Brouwer, E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454–1457.
Google Scholar | Medline | ISI11. ten Tije, AJ, Verweij, J, Loos, WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665–685.
Google Scholar | Crossref | Medline | ISI12. Brufsky, A . Nab-paclitaxel for the treatment of breast cancer: an update across treatment settings. Exp Hematol Oncol 2017; 6: 7.
Google Scholar | Crossref | Medline13. Park, IH, Sohn, JH, Kim, SB, et al. An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. Cancer Res Treat 2017; 49: 569–577.
Google Scholar | Crossref | Medline14. Sparreboom, A, de Jonge, MJ, Verweij, J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer 2002; 38: 18–22.
Google Scholar | Crossref | Medline15. Hong, JW, Lee, IH, Kwak, YH, et al. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther 2007; 6: 3239–3247.
Google Scholar | Crossref | Medline16. Kang, YK, Ryu, MH, Park, SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol 2018; 29: 1220–1226.
Google Scholar | Crossref | Medline17. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
Google Scholar | Crossref | Medline | ISI18. Vogel, CL, Nabholtz, JM. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 1999; 4: 17–33.
Google Scholar | Crossref | Medline19. Llombart-Cussac, A, Pérez-García, JM, Bellet, M, et al. PARSIFAL: a randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer. J Clin Oncol 2020; 38(Suppl.): Abstract 1007.
Google Scholar | Crossref20. Aigner, J, Marmé, F, Smetanay, K, et al. Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice. Anticancer Res 2013; 33: 3407–3413.
Google Scholar | Medline21. Jackisch, C, Lück, HJ, Untch, M, et al. Weekly nab-paclitaxel in metastatic breast cancer – summary and results of an expert panel discussion. Breast Care 2012; 7: 137–143.
Google Scholar | Crossref | Medline22. Umanzor, G, Cutler, DL, Barrios, FJ, et al. Oral paclitaxel with encequidar: the first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a phase III clinical study in metastatic breast cancer. Cancer Res 2020; 80(Suppl. 4): Abstract GS6-01.
Google Scholar23. Umanzor, G, Rugo, HS, Barrios, FJ, et al. Oral paclitaxel and encequidar (oPac+E) versus IV paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (study KX-ORAX-001): progression free survival (PFS) and overall survival (OS) updates. Cancer Res 2021; 81(Suppl. 4): Abstract PD1-08.
Google Scholar24. O’Shaughnessy, J, Schwartzberg, L, Piccart, M, et al. Results from CONTESSA: a phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. Cancer Res 2021; 81(Suppl. 4): Abstract GS4-01.
Google Scholar25. Seidman, AD, Schwartzberg, LS, Gudena, VK, et al. Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study. J Clin Oncol 2018; 36(Suppl.): 1042, https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.1042
Google Scholar | Crossref